OpenURL Connection Search

Select item for more details and to access through your institution.

STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
Published in:
Journal of Hematology & Oncology, 2015, v. 8, n. 1, p. 1, doi. 10.1186/s13045-015-0160-2
By:
- Subbiah, Vivek;
- McMahon, Caitlin;
- Patel, Shreyaskumar;
- Zinner, Ralph;
- Silva, Elvio G.;
- Elvin, Julia A.;
- Subbiah, Ishwaria M.;
- Ohaji, Chimela;
- Ganeshan, Dhakshina Moorthy;
- Anand, Deepa;
- Levenback, Charles F.;
- Berry, Jenny;
- Brennan, Tim;
- Chmielecki, Juliann;
- Chalmers, Zachary R.;
- Mayfield, John;
- Miller, Vincent A.;
- Stephens, Philip J.;
- Ross, Jeffrey S.;
- Ali, Siraj M.
Publication type:
Article
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Published in:
Oncologist, 2017, v. 22, n. 12, p. 1478, doi. 10.1634/theoncologist.2017-0242
By:
- Johnson, Adrienne;
- Severson, Eric;
- Gay, Laurie;
- Vergilio, Jo‐Anne;
- Elvin, Julia;
- Suh, James;
- Daniel, Sugganth;
- Covert, Mandy;
- Frampton, Garrett M.;
- Hsu, Sigmund;
- Lesser, Glenn J.;
- Stogner‐Underwood, Kimberly;
- Mott, Ryan T.;
- Rush, Sarah Z.;
- Stanke, Jennifer J.;
- Dahiya, Sonika;
- Sun, James;
- Reddy, Prasanth;
- Chalmers, Zachary R.;
- Erlich, Rachel
Publication type:
Article
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
Published in:
Oncologist, 2017, v. 22, n. 4, p. 416, doi. 10.1634/theoncologist.2016-0310
By:
- Elvin, Julia A.;
- Gay, Laurie M.;
- Ort, Rita;
- Shuluk, Joseph;
- Long, Jennifer;
- Shelley, Lauren;
- Lee, Ronald;
- Chalmers, Zachary R.;
- Frampton, Garrett M.;
- Ali, Siraj M.;
- Schrock, Alexa B.;
- Miller, Vincent A.;
- Stephens, Philip J.;
- Ross, Jeffrey S.;
- Frank, Richard
Publication type:
Article
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
Published in:
Pigment Cell & Melanoma Research, 2018, v. 31, n. 3, p. 432, doi. 10.1111/pcmr.12674
By:
- Johnson, Douglas B.;
- Childress, Merrida A.;
- Chalmers, Zachary R.;
- Frampton, Garrett M.;
- Ali, Siraj M.;
- Rubinstein, Samuel M.;
- Fabrizio, David;
- Ross, Jeffrey S.;
- Balasubramanian, Sohail;
- Miller, Vincent A.;
- Stephens, Philip J.;
- Sosman, Jeffrey A.;
- Lovly, Christine M.
Publication type:
Article
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Published in:
Genome Medicine, 2017, v. 9, p. 1, doi. 10.1186/s13073-017-0424-2
By:
- Chalmers, Zachary R.;
- Connelly, Caitlin F.;
- Fabrizio, David;
- Gay, Laurie;
- Ali, Siraj M.;
- Ennis, Riley;
- Schrock, Alexa;
- Campbell, Brittany;
- Shlien, Adam;
- Chmielecki, Juliann;
- Huang, Franklin;
- Yuting He;
- Sun, James;
- Tabori, Uri;
- Kennedy, Mark;
- Lieber, Daniel S.;
- Roels, Steven;
- White, Jared;
- Otto, Geoffrey A.;
- Ross, Jeffrey S.
Publication type:
Article

Found: 5

STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.